Literature DB >> 16171777

Interaction of measles virus vectors with Auger electron emitting radioisotopes.

David Dingli1, Kah-Whye Peng, Mary E Harvey, Sompong Vongpunsawad, Elizabeth R Bergert, Robert A Kyle, Roberto Cattaneo, John C Morris, Stephen J Russell.   

Abstract

A recombinant measles virus (MV) expressing the sodium iodide symporter (NIS) is being considered for therapy of advanced multiple myeloma. Auger electrons selectively damage cells in which the isotope decays. We hypothesized that the Auger electron emitting isotope 125I can be used to control viral proliferation. MV was engineered to express both carcinoembryonic antigen and NIS (MV-NICE). Cells were infected with MV-NICE and exposed to 125I with appropriate controls. MV-NICE replication in vitro is inhibited by the selective uptake of 125I by cells expressing NIS. Auger electron damage is partly mediated by free radicals and abrogated by glutathione. In myeloma xenografts, control of MV-NICE with 125I was not possible under the conditions of the experiment. MV-NICE does not replicate faster in the presence of radiation. Auger electron emitting isotopes effectively stop propagation of MV vectors expressing NIS in vitro. Additional work is necessary to translate these observations in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16171777     DOI: 10.1016/j.bbrc.2005.08.261

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Intelligent design: combination therapy with oncolytic viruses.

Authors:  Kathryn Ottolino-Perry; Jean-Simon Diallo; Brian D Lichty; John C Bell; J Andrea McCart
Journal:  Mol Ther       Date:  2009-12-22       Impact factor: 11.454

2.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Authors:  K-W Peng; R Myers; A Greenslade; E Mader; S Greiner; M J Federspiel; A Dispenzieri; S J Russell
Journal:  Gene Ther       Date:  2012-04-05       Impact factor: 5.250

3.  Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

Authors:  Chunsheng Liu; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2010-03-16       Impact factor: 11.454

Review 4.  The Na+/I- symporter (NIS): mechanism and medical impact.

Authors:  Carla Portulano; Monika Paroder-Belenitsky; Nancy Carrasco
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

5.  Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.

Authors:  Camilo Ayala-Breton; Glen N Barber; Stephen J Russell; Kah-Whye Peng
Journal:  Hum Gene Ther       Date:  2012-02-07       Impact factor: 5.695

6.  Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.

Authors:  D Dingli; C Offord; R Myers; K-W Peng; T W Carr; K Josic; S J Russell; Z Bajzer
Journal:  Cancer Gene Ther       Date:  2009-06-05       Impact factor: 5.987

Review 7.  Measles virus for cancer therapy.

Authors:  S J Russell; K W Peng
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

8.  Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.

Authors:  R M Myers; S M Greiner; M E Harvey; G Griesmann; M J Kuffel; S A Buhrow; J M Reid; M Federspiel; M M Ames; D Dingli; K Schweikart; A Welch; A Dispenzieri; K-W Peng; S J Russell
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

Review 9.  Auger processes in the 21st century.

Authors:  Roger W Howell
Journal:  Int J Radiat Biol       Date:  2008-12       Impact factor: 2.694

10.  Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.

Authors:  Camilo Ayala-Breton; Lukkana Suksanpaisan; Emily K Mader; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2013-07-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.